Literature DB >> 30590718

Fate alteration of bone marrow-derived macrophages ameliorates kidney fibrosis in murine model of unilateral ureteral obstruction.

Ying Yang1,2, Xiaojian Feng2, Xinyan Liu2, Ying Wang2, Min Hu3, Qi Cao4, Ziyan Zhang1, Linxia Zhao1, Jianlin Zhang1, Rui Guo1, Hailong Wang1, Xi Qiao2, Lihua Wang2, Guoping Zheng1,3.   

Abstract

BACKGROUND: Renal fibrosis is a key pathological feature and final common pathway leading to end-stage kidney failure in many chronic kidney diseases. Myofibroblast is the master player in renal fibrosis. However, myofibroblasts are heterogeneous. Recent studies show that bone marrow-derived macrophages transform into myofibroblasts by transforming growth factor (TGF)-β-induced macrophage-myofibroblast transition (MMT) in renal fibrosis.
METHODS: TGF-β signaling was redirected by inhibition of β-catenin/T-cell factor (TCF) to increase β-catenin/Foxo in bone marrow-derived macrophages. A kidney fibrosis model of unilateral ureteral obstruction was performed in EGFP bone marrow chimera mouse. MMT was examined by flow cytometry analysis of GFP+F4/80+α-SMA+ cells from unilateral ureteral obstruction (UUO) kidney, and by immunofluorescent staining of bone marrow-derived macrophages in vitro. Inflammatory and anti-inflammatory cytokines were analysis by enzyme-linked immunosorbent assay.
RESULTS: Inhibition of β-catenin/TCF by ICG-001 combined with TGF-β1 treatment increased β-catenin/Foxo1, reduced the MMT and inflammatory cytokine production by bone marrow-derived macrophages, and thereby, reduced kidney fibrosis in the UUO model.
CONCLUSIONS: Our results demonstrate that diversion of β-catenin from TCF to Foxo1-mediated transcription not only inhibits the β-catenin/TCF-mediated fibrotic effect of TGF-β, but also enhances its anti-inflammatory action, allowing therapeutic use of TGF-β to reduce both inflammation and fibrosis at least partially by changing the fate of bone marrow-derived macrophages.
© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  Foxo; bone-marrow; fibrosis; macrophage; β-catenin

Mesh:

Substances:

Year:  2019        PMID: 30590718     DOI: 10.1093/ndt/gfy381

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transition.

Authors:  Junzhe Chen; Ying Tang; Yu Zhong; Biao Wei; Xiao-Ru Huang; Patrick Ming-Kuen Tang; Anping Xu; Hui-Yao Lan
Journal:  Mol Ther       Date:  2022-07-05       Impact factor: 12.910

Review 2.  Macrophage Phenotype and Fibrosis in Diabetic Nephropathy.

Authors:  Priscila Calle; Georgina Hotter
Journal:  Int J Mol Sci       Date:  2020-04-17       Impact factor: 5.923

Review 3.  TGF-β1 Signaling: Immune Dynamics of Chronic Kidney Diseases.

Authors:  Philip Chiu-Tsun Tang; Alex Siu-Wing Chan; Cai-Bin Zhang; Cristina Alexandra García Córdoba; Ying-Ying Zhang; Ka-Fai To; Kam-Tong Leung; Hui-Yao Lan; Patrick Ming-Kuen Tang
Journal:  Front Med (Lausanne)       Date:  2021-02-25

Review 4.  The Essential Role of FoxO1 in the Regulation of Macrophage Function.

Authors:  Shan Jie Rong; Chun Liang Yang; Fa Xi Wang; Fei Sun; Jia Hui Luo; Tian Tian Yue; Ping Yang; Qilin Yu; Shu Zhang; Cong-Yi Wang
Journal:  Biomed Res Int       Date:  2022-08-11       Impact factor: 3.246

Review 5.  The role of the macrophage-to-myofibroblast transition in renal fibrosis.

Authors:  Jia Wei; Zihao Xu; Xiang Yan
Journal:  Front Immunol       Date:  2022-08-05       Impact factor: 8.786

6.  Neural transcription factor Pou4f1 promotes renal fibrosis via macrophage-myofibroblast transition.

Authors:  Patrick Ming-Kuen Tang; Ying-Ying Zhang; Jun Xiao; Philip Chiu-Tsun Tang; Jeff Yat-Fai Chung; Jinhong Li; Vivian Weiwen Xue; Xiao-Ru Huang; Charing Ching-Ning Chong; Chi-Fai Ng; Tin-Lap Lee; Ka-Fai To; David J Nikolic-Paterson; Hui-Yao Lan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-08-11       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.